KBY Biotech Indexv0.0.34
Search
← Pipeline|PCV-2362

PCV-2362

Phase 1
By Vaxcyte
Source: Trial-derived·Trials: 2
Modality
Fusion Protein
MOA
RAS(ON)i
Target
TIGIT
Pathway
PD-1/PD-L1
PSPMGNSCLC
Development Pipeline
Preclinical
~Sep 2015
→ ~Dec 2016
Phase 1
Mar 2017
→ Aug 2031
Phase 1Current
NCT05783562
1,612 pts·PSP
2017-03→2026-06·Completed
NCT06301264
2,951 pts·MG
2019-01→2031-08·Active
4,563 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-06-233mo awayInterim· PSP
2031-08-105.4y awayInterim· MG
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1
Complet…
P1
Active
Catalysts
Interim
2026-06-23 · 3mo away
PSP
Interim
2031-08-10 · 5.4y away
MG
ActiveCompleted|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT05783562Phase 1PSPCompleted1612OS
NCT06301264Phase 1MGActive2951PASI75
Competitors (10)
DrugCompanyPhaseTargetMOA
ZanuderotideJohnson & JohnsonPhase 2/3TIGITGLP-1/GIP
MRK-6781Merck & CoApprovedTIGITRAS(ON)i
SNY-9073SanofiPhase 2B7-H3RAS(ON)i
PexamavacamtenDaiichi SankyoNDA/BLATIGITCD3xCD20
TixarelsinVertex PharmaPhase 1ALKRAS(ON)i
BNT-5232BioNTechNDA/BLATIGITPARPi
ALN-8757AlnylamPreclinicalTIGITCFTRmod
MiritinibNeurocrinePhase 3TIGITSTINGag
FixatuximabLegend BiotechPreclinicalCFTRRAS(ON)i
ION-1378IonisNDA/BLATROP-2RAS(ON)i